Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul 16;114(3):596-9.
doi: 10.1182/blood-2009-02-203935. Epub 2009 May 26.

Type 17 CD8+ T cells display enhanced antitumor immunity

Christian S Hinrichs  1 , Andrew Kaiser, Chrystal M Paulos, Lydie Cassard, Luis Sanchez-Perez, Bianca Heemskerk, Claudia Wrzesinski, Zachary A Borman, Pawel Muranski, Nicholas P Restifo
Affiliations

Type 17 CD8+ T cells display enhanced antitumor immunity

Christian S Hinrichs et al. Blood. .

Abstract

Interleukin-17 (IL-17)-secreting CD8(+) T cells have been described, but they have not been thoroughly studied and they do not have a known role in cancer immunotherapy. We skewed CD8(+) T cells to secrete IL-17 through priming in Th17-polarizing conditions. IL-17-producing CD8(+) T cells demonstrated reduced expression of Eomes and diminished cytolytic differentiation in vitro. However, after adoptive transfer, these cells converted to interferon-gamma-producing effector cells and mediated regression of large, established tumors. This improved antitumor immunity was associated with increased expression of IL-7R-alpha, decreased expression of killer cell lectin-like receptor G1, and enhanced persistence of the transferred cells. This report is the first description of a cancer therapy with IL-17-secreting CD8(+) T cells. These findings have implications for the improvement of CD8(+) T cell-based adoptive immunotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Type 17–polarized CD8+ T cells produced IL-17 and were diverted from cytolytic differentiation. Pmel-1/Thy1.1 CD8+ T cells were primed in IL-17–polarizing conditions or in nonpolarizing conditions and then expanded with IL-2. (A-D) The cells were then cocultured overnight with target splenocytes pulsed with hgp10025-33 peptide. Production of IL-17, CCL20, IFN-γ, and IL-2 was determined by enzyme-linked immunosorbent assay. (E) Four-hour 51Cr release cytolysis assays were performed. Target cells were pulsed with the peptide indicated in the figure legend. Error bars indicate the SEM. (F) Real-time reverse-transcribed polymerase chain reaction was performed to assess expression of the indicated transcription factors. Expression relative to β-actin is displayed. Error bars represent the SEM.
Figure 2
Figure 2
Type 17–polarized CD8+ T cells mediated enhanced antitumor immunity and demonstrated greater persistence. A total of 106 pmel-1/Thy1.1 CD8+ T cells were adoptively transferred into mice bearing established, vascularized B16F10 melanomas. Recipient mice were pretreated with 5 Gy total body irradiation, and they received adjuvant vaccine and IL-2 in conjunction with cell therapy. (A) Serial tumor measurements were obtained and tumor areas were calculated. Error bars indicate the SEM (N = 5). The experiment shown is representative of 3 independent experiments. (B) Expansion and persistence of adoptively transferred cells. The spleens of 3 mice per condition were examined at each time point. Error bars represent the SEM. (C-D) Expression of killer cell lectin-like receptor G1 and IL-7Rα by transferred cells after infusion as determined by flow cytometry gated on Thy1.1+ cells. The data represent 3 spleens per condition at each time point. Error bars represent the SEM. (E) Flow cytometric determination of intracellular cytokines after infusion. The dot plots are gated on Thy1.1+ cells from a pool of 3 spleens per condition at each time point.
See this image and copyright information in PMC

References

    1. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270. - PMC - PubMed
    1. Heslop HE, Brenner MK. The clone ranger? Mol Ther. 2008;16:1520–1521. - PubMed
    1. Bollard CM, Gottschalk S, Leen AM, et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–2845. - PMC - PubMed
    1. Coccoris M, de Witte MA, Schumacher TN. Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther. 2005;5:583–593. - PubMed
    1. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129. - PMC - PubMed

Publication types

MeSH terms